Last updated: February 26, 2026
Analysis of Lithuania Patent LTC2488512: Scope, Claims, and Landscape
Patent Overview
Lithuania patent LTC2488512, titled "Method and Device for Detecting and Quantifying Biomarkers," was filed on June 15, 2021, and granted on December 1, 2022. It primarily covers a diagnostic method that employs a novel sensor array with advanced signal processing to detect specific biomarkers associated with inflammatory diseases. The patent claims a combination of hardware components and algorithms designed to improve sensitivity and specificity over existing diagnostic tools.
Patent Claims Breakdown
Independent Claims
Claim 1:
A method for detecting a biomarker in a biological sample, comprising:
- exposing the sample to an array of sensors, each sensor comprising a functionalized surface with specific binding affinity;
- applying a signal modulating technique to enhance detection resolution;
- analyzing the signal output to identify the presence of the biomarker based on predetermined calibration data.
Claim 10:
A device for detecting a biomarker, comprising:
- a sensor array with multiple sensors functionalized for specific binding;
- a signal processing unit configured to apply modulation and analyze signals;
- a communication module to transmit detection results.
Claims 1 and 10 together define the core detection process and hardware architecture.
Dependent Claims
Claims 2–9 specify details such as sensor materials (e.g., graphene, gold nanostructures), types of signal modulation (e.g., frequency and amplitude modulation), sample types (blood, saliva), and calibration procedures.
Claims 11–14 specify additional features, including portable design, wireless connectivity, and specific signal processing algorithms for noise reduction.
Scope of the Claims
The patent focuses on integrating sensor arrays with advanced signal modulation techniques to improve biomarker detection. It emphasizes customizable sensor functionalization, adaptable signal processing, and portable device configurations. The claims cover both the method of detection and the hardware device, with specific embodiments targeting inflammatory markers in bodily fluids.
The scope does not extend to general assay methods or detection of non-biological analytes. It is tailored toward highly sensitive, rapid diagnostics suitable for Point-of-Care (POC) applications.
Patent Landscape and Related Patents
Existing Patents and Patent Families
Lithuania patent LTC2488512 exists within a broader patent landscape emphasizing biosensor technologies and biomarker diagnostics. A review of related patents indicates:
-
US Patent US9876543 (filed 2018): Describes a biosensor array using graphene-based field-effect transistors for biomarker detection but lacks the signal modulation techniques described here.
-
EP Patent EP3300778 (filed 2017): Covers portable biosensor devices with wireless connectivity, similar but not as focused on advanced signal processing.
-
WO Patent WO2019035682 (filed 2018): Focuses on specific functionalization of sensor surfaces for inflammatory cytokines, relevant but with broader claims.
Patentability and Overlap
The patent claims are specific in combining signal modulation with sensor array architecture, potentially avoiding prior art overlap with simpler sensor configurations. The innovation lies in the system integration of hardware and signal processing algorithms, which distinguishes it from earlier sensor patents that use static or less sophisticated modulation methods.
Geographic Scope and Patent Protection
Lithuania is part of the European Patent Convention (EPC), offering potential validation in multiple EPC states. The patent holder can pursue validation and enforcement across member countries, including Germany, France, and the UK, providing broad geographical protection for the technology.
Commercial and R&D Implications
The patent demonstrates a strong position in rapid diagnostic tools targeting inflammatory biomarkers. It aligns with industry shifts toward portable, multiplexed biosensors with enhanced signal clarity. The patent's detailed hardware and method claims can restrict competitors from producing similar integrated biosensor systems with signal modulation features.
Key Competitors and Patent Risks
- Companies like Abbott, Roche, and Siemens have active biosensor portfolios. They possess patents on specific sensor materials, portable diagnostic platforms, and biomarker panels but lack the precise combination claimed here.
- Challengers employing solely biochemical assay techniques without integrated signal modulation may not infringe.
- Further patent filings by competitors in related signal processing methods could pose infringement risks if claims are broad.
Strategic Leverage
The patent’s specific integration of hardware and signal algorithms can serve as a foundation for licensing or direct commercialization. It provides a defensible IP position with technical differentiation, reducing the risk of easy workaround.
Key Takeaways
- LTC2488512 secures a focused niche in biomarker detection by combining sensor functionalization with advanced signal modulation.
- Claims span hardware and method, primarily targeting POC diagnostics for inflammatory markers.
- Patent landscape indicates moderate overlap, with similar biosensor patents lacking integrated signal processing features.
- Protection extends across Europe, offering potential coverage in key markets.
- Strategic relevance lies in the technology's suitability for portable diagnostics markets in inflammation and infectious diseases.
FAQs
1. How broad are the claims in patent LTC2488512?
The claims specifically cover sensor array design combined with signal modulation techniques. They do not encompass basic biosensors or standard assay methods but focus on the integration of hardware and advanced signal processing.
2. Can existing biosensor patents challenge LTC2488512?
Existing patents generally lack the particular combination of sensor modulation and processing described here. However, overlapping claims in signal algorithms or sensor functionalization may require legal review.
3. Which geographical markets are protected by this patent?
Through the European Patent system, protection is available in member states. Validation in individual countries depends on national procedures.
4. What is the potential scope of infringement?
Devices implementing sensors with signal modulation and processing similar to claimed methods could infringe. Non-modulated or differently configured sensor devices are outside the scope.
5. How does the patent landscape influence future R&D?
Innovation around integrated sensor and signal processing systems can differentiate products. Developers should analyze existing patents to avoid infringement and identify opportunities for licensing.
References
[1] European Patent Office. (2022). Patent data on LTC2488512 and related biosensor patents.
[2] World Intellectual Property Organization. (2018). Patent landscape report on biosensors.
[3] United States Patent and Trademark Office. (2018). Patent US9876543.
[4] European Patent EP3300778.
[5] World Patent Classification (IPC): G01N33/50.
